Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $434.01M.
ENTERPRISE VALUE (EV)
$434.01M
Immix Biopharma, Inc.
Market Cap
$527.94M
Enterprise Value (EV)
$434.01M
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Immix Biopharma, Inc. (IMMX) | $527.94M | $434.01M |
| Monopar Therapeutics Inc. (MNPR)vs › | $522.68M | $470.03M |
| ProKidney Corp. (PROK)vs › | $536.32M | $464.98M |
| Crescent Biopharma, Inc. (CBIO)vs › | $520.39M | $350.23M |
| Altimmune, Inc. (ALT)vs › | $519.25M | $491.94M |
| Delcath Systems, Inc. (DCTH)vs › | $539.58M | $494.52M |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $540.42M | $525.05M |
| 908 Devices Inc. (MASS)vs › | $511.14M | $452.42M |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $549.33M | $530.16M |
| Nuvectis Pharma, Inc. (NVCT)vs › | $550.37M | $528.21M |
Market Cap
$527.94M
Total Debt
$0.00
Cash
$93.93M
Enterprise Value
$434.01M
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
